Clinical Trial Update: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration [Phase 1, Phase 2]

View source ↗

Summary

Ongoing phase 1/2 clinical trial evaluating ORIC-114 in patients with advanced solid tumors harboring EGFR or HER2 alterations, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ORIC-114

Snippet

Sponsor: ORIC Pharmaceuticals | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING